1Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thromhin inhihitors[J]. diol Clin, 2008, 26:169-187.
2Swan SK, Hursting MJ. The pharmacokinetics and pharmaeodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction[J]. Pharmacotherapy, 2000, 20:318- 329.
3Fareed, Jeske WP. Small-molecule direct antithrombins: argatroban[J]. Best Pratt Res Clin Haematol, 2004, 7:127-138.
4Walenga JM, Ahmad S, Hoppensteadt D, et al. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin induced thrombocytopenia[J]. Thromb Res, 2002, 105:401-405.
5Swan SK, St Peter JV, Lambrecht LJ, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects[J]. Pharmacotherapy, 2000, 20 :756-770.
6Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction[J]. Pharmacotherapy, 2000, 20:318-329.
7Murray PT, Reddy BV, Grossman EJ, et al, A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease[J]. Kidney Int, 2004,66:2446-2453.
8Ota K, Kawaguchi H, Nakagawa S, et al. Clinical evaluation of a new thrombin inhibitor available for haemodialysis [J]. Proc Eur Dial Transplant Assoc, 1983, 20:144-149.
9Matsuo T, Nakao K, Yamada T, et al. Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuit[J]. Thromb Res, 1986, 41:33-41.
10Matsuo T, Chikahira Y, Yamada T, et al. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis [J]. Thromb Res, 1988, 52:165-171.
9Link A, PtSss J, Bfihm M. Diagnosis and treatment of heparin- induced thrombocytopenia [ J ] . Dtsch Med Wochenschr, 2011, 136 ( 18 ) : 953-962.
10Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment [ J ] . Am J Cardiovasc Drugs, 2005, 5 ( 5 ) : 291-305.
